B-MS to file liso-cel BLA based on Phase I data

9 December 2019
bristol_myers_squibb_big

US pharma major Bristol-Myers Squibb (NYSE: BMY) announced over the weekend that its Phase I study of lisocabtagene maraleucel (liso-cel) met its primary and secondary endpoints while demonstrating durable responses.

Liso-cel is a CD19-directed CAR-T cell therapy with a defined composition of purified CD8+ and CD4+ CAR-T cells, and it is being investigated in the TRANSCEND NHL 001 trial in relapsed/refractory large B-cell lymphomas.

The latest results were presented at the ongoing ASH event.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology